Low-FODMAP Diet

The FODMAP concept at Monash University

The term FODMAP was introduced by Peter Gibson and Susan Shepherd of Monash University in Australia in a 2005 paper in Alimentary Pharmacology and Therapeutics. That paper was a hypothesis article about susceptibility to Crohn's disease, not about irritable bowel syndrome. It proposed that excessive delivery of highly fermentable, poorly absorbed short-chain carbohydrates and polyols to the distal small intestine and colon could be a dietary factor in susceptibility, and it gave these carbohydrates the designation FODMAPs.

The abstract presents this as a hypothesis, supported by indirect evidence such as rising intake of these carbohydrates in Western societies and earlier documented effects of ingesting them on the bowel. The application to irritable bowel syndrome and other functional gut symptoms developed afterward. The sources reviewed for this page do not give a dated account of the first trials in irritable bowel syndrome, so this page does not assign them a year.

From research concept to clinical guidance

In 2010 Gibson and Shepherd published a review in the Journal of Gastroenterology and Hepatology describing the evidence for restricting FODMAPs to control functional gastrointestinal symptoms. The authors, both associated with Monash University, concluded that the evidence base was sufficiently strong to recommend widespread application. That conclusion comes from the originators of the approach and is best read alongside the independent guidelines and reviews described later on this page.

Professional bodies then placed the diet within their guidance. The British Dietetic Association published its first dietary guidelines for irritable bowel syndrome in adults in 2012 and updated them in 2016. The National Institute for Health and Care Excellence guideline on irritable bowel syndrome in adults was published in 2008 and last updated in 2017. The American College of Gastroenterology issued its first guideline on irritable bowel syndrome management in 2021, and the American Gastroenterological Association published a clinical practice update on diet in irritable bowel syndrome in 2022.

What the acronym stands for

The acronym FODMAP groups fermentable carbohydrates by type: oligosaccharides, then disaccharides, then monosaccharides, with polyols as the fourth class. These are short-chain carbohydrates that are poorly absorbed or rapidly fermented in the gut. In the 2010 review the group is described as comprising a monosaccharide (fructose), a disaccharide (lactose), oligosaccharides (fructans and galactans) and polyols.

The proposed mechanism in that review is that ingestion increases delivery of readily fermentable material and water to the distal small intestine and proximal colon, which is likely to cause distension of the bowel and so induce functional gut symptoms. The authors describe this as a likely explanation rather than a demonstrated chain of events, and later reviews cited below describe the mechanisms as incompletely resolved.

Names for the approach

The approach is called the low-FODMAP diet in most sources, and the Monash University program and its materials use the name Monash FODMAP. Guidelines also group it with other dietary strategies under broader labels: NICE refers to single food avoidance and exclusion diets, giving a low FODMAP diet as an example, while the American Gastroenterological Association and a 2026 cohort study use the term restrictive diets.

The diet is distinct from the Gluten-Free Diet, which has its own Machipedia page. Some FODMAPs and gluten-containing foods overlap, but the two approaches are defined differently, and trials have compared them directly. The low-FODMAP diet belongs to the family described on the Machipedia page Dietary Approaches.

Three phases in guideline language

The American Gastroenterological Association clinical practice update describes the low-FODMAP diet as having three phases: a restriction phase lasting no more than 4 to 6 weeks, reintroduction of FODMAP foods, and personalization based on the results of reintroduction. Monash University describes the same pattern in general terms, with a period of strict restriction followed by gradual reintroduction of certain foods.

The aim of the later phases, as these sources describe them, is to identify which FODMAP groups are associated with a person's symptoms so that restriction is narrowed rather than maintained broadly. The AGA update also states that a specific diet intervention should be attempted for a predetermined length of time and abandoned for another option if there is no clinical response. This page does not give food lists, quantities or stepwise instructions.

Who delivers it

Sources consistently describe the diet as something led by a trained professional. The 2010 review states that it requires expert delivery by a dietitian trained in the diet. The British Dietetic Association guideline places low-FODMAP advice as second-line dietary advice to be provided by a dietitian. The AGA update advises referral to a registered dietitian nutritionist for patients who are willing to collaborate or cannot implement dietary changes alone.

NICE words this more broadly, advising that further dietary management such as single food avoidance and exclusion diets be offered by a healthcare professional with expertise in dietary management. Monash University states that the diet is best followed under the supervision of a qualified dietitian or healthcare professional. The profession of Dietetics and the field of Nutritional Therapy each have their own Machipedia pages.

Place among other dietary options

The British Dietetic Association simplified its irritable bowel syndrome dietary algorithm to first-line advice on healthy eating, which any healthcare professional can provide, and second-line low-FODMAP advice from a dietitian. NICE similarly offers further dietary management, including a low FODMAP diet as an example, when symptoms persist despite general lifestyle and dietary advice.

The AGA update calls the low-FODMAP diet currently the most evidence-based diet intervention for irritable bowel syndrome, and also states that healthy eating advice as described by NICE offers benefit to a subset of patients. These positions describe a sequence of options rather than a requirement to use the low-FODMAP diet.

Irritable bowel syndrome and functional gut symptoms

The principal use is the management of symptoms in irritable bowel syndrome. Gibson and Shepherd describe the approach as aimed at controlling functional gastrointestinal symptoms, and the American College of Gastroenterology guideline recommends a limited trial of a low FODMAP diet in patients with irritable bowel syndrome to improve global symptoms.

The AGA update states that most patients with irritable bowel syndrome associate their symptoms with eating, and that mounting evidence supports dietary modifications such as the low-FODMAP diet as a primary treatment for symptoms. These statements concern symptom management, not the cause of the condition, and none of the sources reviewed describe the diet as removing the underlying disorder.

Other digestive conditions that have been studied

A 2025 systematic review of randomized trials included 14 trials: 10 in irritable bowel syndrome, 3 in inflammatory bowel disease and 1 in reflux disease that had not responded to proton pump inhibitors. In inflammatory bowel disease the improvements were mainly in functional gastrointestinal symptoms, and in reflux disease no clear benefit was shown.

Evidence from irritable bowel syndrome should not be carried over to these other conditions. The review authors describe the low-FODMAP diet as a potential supportive approach in some gastrointestinal disorders, not as a universal need, and note that less restrictive changes may be enough for some people.

Randomized trials in irritable bowel syndrome

The 2025 systematic review of randomized trials found that most of the 10 irritable bowel syndrome trials reported significant improvements in abdominal pain, bloating and quality of life compared with control diets. Interventions lasted from 3 to 12 weeks and all compared the low-FODMAP diet with another diet. Differences in study design, duration, comparator diets and outcomes prevented a meta-analysis.

A 2024 network meta-analysis of 23 randomized trials with 1,689 participants found the low-FODMAP diet statistically better than a standard diet on the irritable bowel syndrome severity scale (mean difference -46.29) and on irritable bowel syndrome quality of life. The authors called for larger trials making direct comparisons.

Comparison with other diets

In the same network meta-analysis, the direct comparison found no statistically significant difference between a gluten-free diet and either the low-FODMAP diet or a standard diet. In the ranking, the Mediterranean diet showed the greatest improvement on several outcomes, followed by the low-FODMAP diet alone or combined with a gluten-free diet. The authors note that head-to-head trials, particularly for the Mediterranean diet, are needed.

The British Dietetic Association review appraised 86 studies and produced 46 evidence statements and 15 clinical recommendations on diet in adults with irritable bowel syndrome. The low-FODMAP diet is one of several dietary topics in that review, alongside fiber, gluten, probiotics and healthy eating.

Long-term use

A 2025 meta-analysis of long-term use, defined as at least 6 months, included five studies with 324 patients. It reported reductions in overall gastrointestinal symptoms, anxiety and depression and an improvement in quality of life, but no improvement in sleep quality. The authors state that further research is needed. With so few studies, the findings are limited, and the Kuźmin review calls for trials with standardized endpoints and longer follow-up.

Gut microbiota

A 2025 meta-analysis of 10 randomized trials with 590 participants compared low-FODMAP and normal diets on measures of intestinal flora. It reported a significant overall difference (standardized mean difference 0.33) with substantial heterogeneity, and no significant difference in the subgroup of people with irritable bowel syndrome. The authors conclude that more high-quality studies are needed, including on long-term effects. This page reads only the abstract of that paper.

Guideline positions

The American College of Gastroenterology recommends a limited trial of a low FODMAP diet in irritable bowel syndrome to improve global symptoms. The AGA update calls it the most evidence-based diet intervention for irritable bowel syndrome, but states that it is an expert review that was not a systematic review and did not formally rate the quality of evidence. The British Dietetic Association positions it as second-line advice from a dietitian, and NICE offers it as an example of further dietary management.

Nutritional adequacy and unnecessary restriction

Because the diet limits a wide range of foods, reviewers describe its restrictive nature and potential long-term effects, including nutritional deficiencies and alterations in gut microbiota, as reasons for clinical supervision by dietitians with expertise in gastrointestinal disorders. The Kuźmin review adds that the diet is not universally necessary and that symptom improvement may sometimes be achieved with less restrictive changes.

The AGA update names people at risk for malnutrition, people who are food insecure and people consuming few culprit foods among those who are poor candidates for restrictive diet interventions. It also advises that an intervention be limited to a predetermined length of time and abandoned if there is no clinical response.

Eating disorders and disordered eating

The AGA update lists people with an eating disorder or an uncontrolled psychiatric disorder among poor candidates for restrictive diet interventions, and advises routine screening for disordered eating or eating disorders by careful dietary history because they are common and often overlooked in gastrointestinal conditions.

A 2026 retrospective cohort study at one tertiary center found that 50 of 285 patients with an eating disorder and a gastroenterology diagnosis (17.5 percent) were prescribed a restrictive diet within 12 months of a gastroenterology consult, including patients not in remission. The authors describe restrictive diets as potentially harmful in people with eating disorders, but the design cannot establish causation, and the study covered restrictive diets in general rather than the low-FODMAP diet alone.

Care boundaries and professional oversight

The ACG guideline also suggests a positive diagnostic strategy for irritable bowel syndrome rather than a diagnosis of exclusion, serologic testing to rule out celiac disease in people with diarrhea symptoms, and fecal calprotectin to rule out inflammatory bowel disease. Changing diet before these questions are addressed is not a substitute for medical assessment, and persistent or changing symptoms are a matter for a clinician.

Training is described by professional and academic bodies. Monash University encourages healthcare professionals to undertake training developed by its experts, and the AGA update points to referral to a registered dietitian nutritionist. The sources reviewed do not describe a protected title or accreditation specific to low-FODMAP practice, and the Gibson and Shepherd reviews were written by the originators of the approach.